Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLD-1433 PDT in BCG-Refractory NMIBC
NCT03053635Phase 1Completed
- Sponsor
- Theralase Technologies Inc.
- Start
- Dec 2016
- Primary completion
- Aug 2018
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of TLD-1433 in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Theralase Technologies Inc. Primary endpoint: Incidence and Severity of Adverse Effects at 180 days. Started Dec 2016; status: completed.
02
Drugs
TLD-1433
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03053635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053635.